To the Editor As representatives of the American College of Nuclear Medicine, we wish to comment on a recent Original Investigation by Kitahara and colleagues1 that has indirectly called into question the safety of the use of sodium iodide I-131, also known as radioactive iodine (RAI).
Safety of RAI therapy for treatment of hyperthyroidism was previously demonstrated using the same large study patient cohort2 as in the study by Kitahara and colleagues. Data presented in the current article1 took a different approach to analysis and did not report on comparison mortality with either the population nor other therapy options, which severely limits this report. The conclusion is highly problematic: the misrepresentation of “modest positive association” as meaning causation is a misleading and dangerous leap.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Grady EE, Zukotynski K, Greenspan BS. Safety of the Use of Radioactive Iodine in Patients With Hyperthyroidism. JAMA Intern Med. 2019;179(12):1738–1739. doi:10.1001/jamainternmed.2019.5120
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: